This negative association between somatotropin treatment and SARS-CoV-2 positivity remained significant and independent after adjustment for several known factors, which may be associated both with the exposure (somatotropin treatment due to GHI) and the outcome (SARS-CoV-2 infection), such as age, gender, low SES, diagnosis of diabetes mellitus, diagnosis of asthma, diagnosis of ADHD, obesity, and low plasma vitamin D3 level. This evidence concerns the gene GH1 and obesity disorder.